Profits rise at Novartis, Merck, Lilly

Good financial results from three Pharma biggies should cheer up those market-watchers who moaned their way through much of last week. Sure, a couple of the profit leaps came at least in part from one-time gains. But increases are always better than the alternative. Here's the news:

  • Novartis reported an estimate-beating 6.8 percent increase in profits. Healthy sales of both Diovan and Gleevec helped, and so did the company's cost-cutting program. So did the weak dollar. But the real stars of the story were generic meds, over-the-counter products, animal drugs, and contact lenses; double-digit growth here offset a decline in brand-name drug sales. Profits rose to $2.32 billion on an 8.6 percent increase in revenue to $9.91 billion.
  • Merck also benefited from the weaker dollar, but its dramatic near-doubling in net income to $3.3 billion was mostly attributed to a one-time $1.4 billion gain on its limited partnership with AstraZeneca. Still, Merck's earnings excluding that item--89 cents--beat analysts' expectations of 86 cents. Revenues didn't meet the street's goals, however; analysts had projected $6.11 billion, but the company reported $5.82 billion. The 0.9 percent growth in sales included a four percentage-point boost off foreign exchange rates.
  • Eli Lilly's sales grew a striking 14 percent, with 8 percentage points of that coming from actual increases in sales volume; foreign exchange rates and price increases accounted for 5 percentage points and 1 percentage point, respectively. A big-gaining drug was Cymbalta, an antidepressant that posted 37 percent growth. Like Merck, Lilly reported a big one-time tax gain, posting net income of $1.06 billion, or 97 cents per share, compared with $508.7 million or 47 cents per share same quarter last year. Restructuring and acquisition costs depressed earnings last year, though; excluding items, the earnings per share gain was actually 9 cents, to 92 cents from 83 cents.

- get the Financial Times news on Novartis
- see the WSJ report
- read the Associated Press' news on Merck
- see the release on Lilly
- check out the Merck and Lilly numbers in the WSJ

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.